세계의 혈액가스 및 전해질 분석기 시장 보고서 :제품 유형별, 모달리티별, 최종사용자별, 지역별(2024-2032년)

The global blood gas and electrolyte analyzer market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.5 Billion by 2032, exhibiting a growth rate (CAGR) of 5.7% during 2024-2032.

Blood gas and electrolyte analyzers refer to medical devices used to measure various parameters, including blood gas (partial pressure of carbon dioxide and oxygen), pH, electrolytes, and metabolites, in a whole blood sample. They are widely utilized for the detection of metabolic imbalances and the measurement of renal and cardiac functions. They also help determine abnormal electrolyte levels in the blood, levels of oxygen or carbon dioxide exchange, and the acid-base balance of the patient. Moreover, they assist in identifying diabetes, blood vessel hemorrhage, and drug consumption. In recent years, blood gas and electrolyte analyzers have gained immense popularity across clinical diagnostic labs and critical care units due to their ease of use, cost-effectiveness, accuracy, and fast results.

Blood Gas and Electrolyte Analyzer Market Trends:

Blood gas and electrolyte analyzers can streamline work processes, minimize errors, require minimum maintenance, and provide accurate results quickly. As a result, the increasing number of patients in intensive care units (ICUs), operating rooms, and emergency departments represent the primary factor driving the market growth. Besides this, the widespread prevalence of chronic diseases, such as diabetes and cardiovascular disorders, and the growing geriatric population that is more susceptible to developing these medical ailments are augmenting the product demand. Additionally, there has been a significant increase in the demand for high throughput, integrated, and automated systems. Along with this, the rising integration of blood gas and electrolyte analyzers with laboratory information systems and electronic medical records to streamline the workflow and enable effective monitoring of patient health is catalyzing the market growth. Furthermore, several leading players are making heavy investments for the development of portable blood gas and electrolyte analyzers with easy-to-use and handle features and minimum maintenance requirements. Other factors, including the shifting preferences toward point-of-care testing (POCT), developments in the healthcare industry, technological advancements, product innovations, and extensive research and development (R&D) activities, are also creating a favorable market outlook.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global blood gas and electrolyte analyzer market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product type, modality and end user.

Breakup by Product Type:

Analyzers

Consumables

Breakup by Modality:

Benchtop

Portable

Breakup by End User:

Hospitals

Clinics

Ambulatory Surgical Centers

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories Inc., Dalko Diagnostics, Erba Group (Transasia Bio-Medicals Ltd.), Medica Corporation, Nova Biomedical Corporation, OPTI Medical Systems Inc. (IDEXX Laboratories), Radiometer Medical ApS (Danaher Corporation), Roche Holding AG, Siemens AG, and WerfenLife S.A.

Key Questions Answered in This Report

• 1. How big is the global blood gas and electrolyte analyzer market?
• 2. What is the expected growth rate of the global blood gas and electrolyte analyzer market during 2024-2032?
• 3. What are the key factors driving the global blood gas and electrolyte analyzer market?
• 4. What has been the impact of COVID-19 on the global blood gas and electrolyte analyzer market?
• 5. What is the breakup of the global blood gas and electrolyte analyzer market based on the product type?
• 6. What is the breakup of the global blood gas and electrolyte analyzer market based on the modality?
• 7. What is the breakup of the global blood gas and electrolyte analyzer market based on the end user?
• 8. What are the key regions in the global blood gas and electrolyte analyzer market?
• 9. Who are the key players/companies in the global blood gas and electrolyte analyzer market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Blood Gas and Electrolyte Analyzer Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product Type

• 6.1 Analyzers
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Consumables
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Modality

• 7.1 Benchtop
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Portable
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Clinics
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Ambulatory Surgical Centers
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Others
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Abbott Laboratories Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Dalko Diagnostics
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 Erba Group (Transasia Bio-Medicals Ltd.)
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 Medica Corporation
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 Nova Biomedical Corporation
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
  • 14.3.6 OPTI Medical Systems Inc. (IDEXX Laboratories)
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
  • 14.3.7 Radiometer Medical ApS (Danaher Corporation)
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 Roche Holding AG
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
  • 14.3.9 Siemens AG
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 WerfenLife S.A.
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio